A randomized, 3-arm study is giving further insight into the effects of levothyroxine monotherapy compared against a thyroid combination therapy and desiccated thyroid extract for management of hypothyroidism, particularly in patients with Thr92AlaD2 polymorphism.
An analysis of patients and providers from endocrine clinics suggests many patients and providers were open to continuing with telehealth practices after the pandemic and many saw little to no limitations with the new practices.
In ENDO 2021 data, approximately one-third of an observed COVID-19 patient population in Italy was still experiencing signs of thyroid inflammation after 3 months,
An analysis of 4k transgender youth and 16k propensity-matched controls is providing insight into the increased risk of conditions adversely impacting the cardiometabolic health of these patients.
Many patients with genetic obesity disorder experience resistance to treatment, including intensive lifestyle therapy.
Evening and late-night preferences of women with GDM is linked to a significantly greater risk of preeclampsia and NICU treatment.
A post-hoc analysis of the AWARD-11 trial indicates that 4.5 mg of dulaglutide was effective in lowering and maintaining A1C levels <7% regardless of baseline levels.
An analysis by investigators from the University of Arkansas suggests children with adrenal insufficiency were 10 times more likely to die from COVID-19 than their counterparts without adrenal insufficiency and COVID-19.
An analysis of more than half a million thyroid hormone users indicates more than 30% were also concurrently receiving a medication known to interfere with thyroid function tests.
A review of observational data suggests the presence of type 2 diabetes could increase risk of developing Parkinson disease and might also speed the progression of motor symptoms.
A trial of more than 20k women from investigators at Kaiser Permanente found there were no significant differences in outcomes among pregnant women undergoing gestational diabetes screenings using the ADA's 1-step approach versus the ACOG's 2-step approach.
Check out the Endocrine Outlook podcast, brought to you by the Endocrinology Network. This episode focuses on semaglutide 1 mg as a weight loss therapy for patients who are obese or overweight.
Compared with a two-step screening method, a one-step approach is associated with more diagnosed incidences of gestational diabetes, despite a lower adherence rate.
Our latest case report from Brady Pregerson, MD, features a woman in her 70s presenting with a facial droop and slurred speech. Can you help determine the correct diagnosis?
Principal investigator of the SURPASS-2 trial discusses the results of the trial and how it informs clinicians on the use of tirzepatide versus currently approved diabetes medications.
Three separate doses of the drug showed benefit when compared to semaglutide.
A major analysis suggests 2 servings of fruit and 3 servings of vegetables daily was linked to the greatest overall longevity and a 12% reduction in risk of death from cardiovascular disease.
After providing insight into the results of the STEP 1 and STEP 3 trials, Dr. Wadden discusses who he believes the responsibility for prescribing these medications will fall unto if semaglutide receives approval as a weight loss agent.
Patients ≥65 years using glargine or detemir, rather than NPH insulin, had lower risk of hospitalizations or emergency department visits due to hypoglycemia.
An analysis of data from 2 major studies suggests women with childhood-onset type 1 diabetes experienced 2.5 fewer reproductive years than their counterparts without diabetes.
Published in late February, results of the STEP 1 and STEP 3 trial give clinicians insight into the effects of 2.4 mg subcutaneous semaglutide as an intervention for weight loss in overweight or obese patients ahead of a potential approval in June 2021.
Results of a two-sample Mendelian randomization analysis suggest vitamin D levels were unlikely to have a large effect on a person's risk for developing type 1 diabetes.
An AHA study suggests nearly 66% of all COVID-19 hospitalizations could be attributed to the presence of obesity, diabetes, hypertension, or heart failure.
An analysis of nearly 500 patients hospitalized with COVID-19 from London suggests dysnatremia could help signal which patients were at an increased risk of complications, including death and need for respiratory support.
